logo

For the Inventor, By the Inventor

Labadie, MO, United States of America

Yvette M Fobian

This inventor holds 47 USPTO granted patents, plus 1 CIPO patent, primarily in Cholesterol Inhibitors. Top assignees: Pharmacia Corporation, G.d. Searle & Company, Pfizer Corporation. Active years: 1999-2011.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yvette M Fobian. Retrieved from https://idiyas.com/inventor/yvette-m-fobian

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 47

% Patents Active = 12.8

 

Average Co-Inventor Count = 12.3

ph-index = 9

Forward Citations = 355(Granted Patents)


Location History:

  • Labadie, MI (US) (2004)
  • Labadie, MO (US) (1999 - 2010)
  • Wildwood, MO (US) (2004 - 2011)

Company Filing History:

goldMedal22 out of 220 
 
Pharmacia Corporation
 patents
silverMedal12 out of 1,323 
 
G.d. Searle & Company
 patents
bronzeMedal5 out of 4,488 
 
Pfizer Corporation
 patents
4. 4 out of 3,289 
 
Monsanto Company
 patents
5. 2 out of 202 
 
Elan Pharmaceuticals, Inc.
 patents
6. 2 out of 523 
 
Pharmacia & Upjohn Company
 patents
7. 1 out of 1 
 
Pharmacia Corporation Global Patent Department
 patent
where one patent can have more than one assignee

Years Active: 1999-2011

Loading Chart...
Loading Chart...
Areas of Expertise:
Cholesterol Ester Transfer Protein
Hydroxamic Acids
Aminoalcohol Derivatives
Protease Inhibitors
Chiral Halogenated Compounds
Fused Heterocycles
Aromatic Sulfones
Diamino Compounds
Substituted Amino Compounds
Cycloalkyl Aminoalcohols
Reverse Aminoalcohols
Mercapto Amino Compounds
47 patents (USPTO):Explore Patents
1. 7902195 - Pyridine [3,4-b] pyrazinones (2011-03-08),
2. 7700658 - (R)-chiral halogenated substituted fused heterocyclic amino compounds useful for inhibiting cholesterol ester transfer protein activity (2010-04-20),
3. 7294642 - 1,3-Diamino-2-hydroxypropane pro-drug derivatives (2007-11-13),
4. 7253211 - (R)-chiral halogenated substituted fused heterocyclic amino compounds useful for inhibiting cholesterol ester transfer protein activity (2007-08-07),
5. 7144897 - Hydroxy alkyl amines (2006-12-05),
6. 7122536 - (R)-chiral halogenated substituted fused heterocyclic amino compounds useful for inhibiting cholesterol ester transfer protein activity (2006-10-17),
7. 7119203 - Piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors (2006-10-10),
8. 6890928 - Aromatic sulfone hydroxamic acids and their use as protease inhibitors (2005-05-10),
9. 6803388 - (R)-Chiral halogenated substituted n,n-bis-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity (2004-10-12),
10. 6765023 - Use of substituted N, N-disubstituted reverse aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity (2004-07-20),
11. 6750233 - Aromatic sulfone hydroxamic acid metalloprotease inhibitor (2004-06-15),
12. 6750228 - Aromatic sulfone hydroxamic acid metalloprotease inhibitor (2004-06-15),
13. 6723753 - Substituted n-benzyl-n-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity (2004-04-20),
14. 6723752 - (R)-chiral halogenated substituted n-benzyl-n-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity (2004-04-20),
15. 6710089 - Substituted N-fused-phenyl-N-benzyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity (2004-03-23),

Title: Yvette M. Fobian: A Trailblazer in Pharmaceutical Innovation

Introduction

Yvette M. Fobian, based in Labadie, Missouri, is a prominent inventor with an impressive portfolio comprising 47 patents. Her innovative work primarily centers around the field of pharmaceuticals, where she has made significant contributions to drug development and therapeutic methods.

Latest Patents

Fobian's latest patents include groundbreaking discoveries such as Pyridine [3,4-b] pyrazinones, where she discloses compounds and their pharmaceutically acceptable salts characterized by a specific structure as detailed in the specification. This invention is complemented by corresponding pharmaceutical compositions and methods of treatment. Another key patent involves (R)-chiral halogenated substituted fused heterocyclic amino compounds, which are innovative inhibitors of cholesteryl ester transfer protein activity. These compounds and their associated methods offer promising treatments for atherosclerosis and other coronary artery diseases through novel preparation processes.

Career Highlights

Throughout her career, Yvette has made notable strides while working with renowned companies such as Pharmacia Corporation and G.D. Searle & Company. Her roles at these organizations have been instrumental in translating her inventive ideas into practical applications, solidifying her standing in the pharmaceutical industry.

Collaborations

Yvette M. Fobian has collaborated with esteemed professionals, including Deborah A. Mischke and Michael B. Tollefson. These collaborations have facilitated the exchange of ideas and expertise, further enhancing her remarkable innovation journey.

Conclusion

With 47 patents to her name, Yvette M. Fobian exemplifies dedication and innovation in the pharmaceutical realm. Her contributions, characterized by significant advancements in drug development and treatment methods, continue to have a lasting impact on health care and medicine.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…